Trials / Conditions / Friedreich's Ataxia

Friedreich's Ataxia

28 registered clinical trials studyying Friedreich's Ataxia — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Cardiac Output and Fatigue in Friedreich's Ataxia NCT07444333	Scott Barbuto	N/A
Recruiting	Electroencephalogram in Patients With Friedreich's Ataxia for the Study of the Structural and Functional Conne NCT07095062	IRCCS Eugenio Medea	N/A
Completed	A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia NCT04102501	Biojiva LLC	Phase 3
Completed	(+) Epicatechin to Treat Friedreich's Ataxia NCT02660112	Ralitza Gavrilova	Phase 2
Completed	A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study) NCT02840669	Adverum Biotechnologies, Inc.	N/A
Completed	Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich' NCT02797080	Amgen	Phase 3
Completed	Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study NCT02593773	Amgen	Phase 3
Recruiting	Biomarkers in Friedreich's Ataxia NCT02497534	University of Florida	—
Completed	A First in Human Study of RT001 in Patients With Friedreich's Ataxia NCT02445794	Biojiva LLC	Phase 1 / Phase 2
Completed	Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia NCT02415127	Amgen	Phase 3
Recruiting	Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA) NCT02316314	Weill Medical College of Cornell University	—
Completed	EPI-743 in Friedreich's Ataxia Point Mutations NCT01962363	University of South Florida	Phase 2
Completed	Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia NCT01898884	Shire	Phase 1
Unknown	An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia NCT01921868	University of South Florida	N/A
Completed	Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia NCT01728064	PTC Therapeutics	Phase 2
Completed	Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND) NCT02179333	University of South Florida	—
Completed	Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROT NCT01303406	Santhera Pharmaceuticals	Phase 3
Completed	Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) NCT02069509	European Friedreich's Ataxia Consortium for Translational Studies	—
Completed	Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia NCT01035671	Penwest Pharmaceuticals Co.	Phase 2
Completed	Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's NCT01016366	H. Lundbeck A/S	Phase 2
Completed	A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia NCT00897221	ApoPharma	Phase 2
Terminated	Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich's Ataxia NCT00803868	University of South Florida	Phase 2 / Phase 3
Completed	Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept NCT00811681	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients NCT00697073	Santhera Pharmaceuticals	Phase 3
Completed	A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia NCT00530127	ApoPharma	Phase 1 / Phase 2
Completed	Efficacy of Epoetin Alfa in Patients With Friedreich's Ataxia NCT00631202	Federico II University	Phase 2
Completed	Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia NCT00537680	Santhera Pharmaceuticals	Phase 3
Completed	A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patie NCT00905268	Santhera Pharmaceuticals	Phase 3